The market value for HIV treatments is expected to increase over the first half of this decade, but then decline during the second half of the decade because of increasing competition from generic versions of key products. In 2018, just under 40 million people were infected with HIV worldwide.
HIV Market To Meet Patent Cliff In 2026-27 But Novel Products Coming
Two-Drug Regimens Make Headway
Market Snapshot: Gilead’s Biktarvy and ViiV’s two-drug regimens are expected to dominate the HIV market over the next few years as market exclusivity losses loom, but drugs with new mechanisms of action, and longer-acting products, might influence market dynamics.
